Indonesia and China Will Sign Drug Safety Accord
The two nations will formalize a new memorandum of understanding to bolster food and drug safety standards.
Updated on Sept. 20, 2026 in Biotech
Live Poll
Do you believe international government partnerships improve the safety of imported food and drugs?
Indonesia and China will sign a new memorandum of understanding on drug and food safety during an upcoming APEC high-level meeting. The agreement aims to enhance regulatory collaboration and includes provisions for vaccine technology investment.
Why it matters
The partnership replaces a previous agreement that expired in June 2024. By strengthening ties between the Indonesian Food and Drug Authority and China's National Medical Products Administration, both nations seek to ensure higher standards for safety, quality, and efficacy.
The agreement includes parameters for regulatory frameworks and technology transfer, specifically focusing on artificial intelligence in Advanced Therapy Medicinal Products. It also facilitates vaccine technology investment and good manufacturing practice certification.
The players
Prabowo Subianto
He is the President of Indonesia who is scheduled to meet with his Chinese counterpart to finalize the safety agreement.
Xi Jinping
He is the President of China who will participate in the high-level APEC meeting where the regulatory pact will be signed.
Taruna Ikrar
He is a representative of the Indonesian Food and Drug Authority who recently discussed AI applications in medical products at Tsinghua University.
The details
The collaboration leverages assessment data between the Indonesian Food and Drug Authority, a World Health Organization-Listed Authority, and the National Medical Products Administration. The deal covers the full spectrum of product lifecycles, including safety monitoring, efficacy testing, and manufacturing quality standards.
Timeline
The previous memorandum of understanding expired in June 2024.
The new agreement will be signed at the upcoming APEC high-level meeting.
The Big Picture
This agreement underscores a trend toward global regulatory convergence, mirroring the standards set by the World Health Organization-Listed Authority framework. The move facilitates a paradigm shift in how international partners validate manufacturing processes and vaccine technologies.
Consumers can expect more consistent safety oversight for pharmaceutical products and vaccines imported between the two nations. The agreement streamlines manufacturing compliance, which may improve the long-term availability of specific therapeutic medicines.
The takeaway
The move demonstrates how bilateral regulatory agreements can effectively stabilize supply chains for critical medical goods. Patients benefit when international authorities coordinate on safety standards to ensure the efficacy of vaccines and food imports.
Further reading
For more on international regulatory developments, visit our Biotech section.
Live Poll
Do you believe international government partnerships improve the safety of imported food and drugs?
